Publications

54 rows, counting the CV or the Scholar profile
Export

Core

Profile fields

Catalogue

2025 Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial Megan L. Matthews · EClinicalMedicine · Scholar only 12 2025 Human genetics identify convergent signals in mitochondrial LACTB-mediated lipid metabolism in cardiovascular-kidney-metabolic syndrome Megan L. Matthews · Cell metabolism 37 (1), 154-168. e7 · Scholar only 30 2025 Hydralazine inhibits cysteamine dioxygenase to treat preeclampsia and senesce glioblastoma Megan L. Matthews · Science Advances · Scholar only 3 2025 Predicting hospitalization and related outcomes in advanced chronic kidney disease: A systematic review, external validation, and development study Megan L. Matthews · Kidney medicine · Scholar only 4 2024 Abstract 2232 Uncharacterized enzymes secernin2/3 and their novel cofactor glyoxylyl group regulate whole body sulfur metabolism Megan L. Matthews · Journal of Biological Chemistry · Scholar only 2024 Activity-Based Protein Profiling of RHBDL4 Reveals Proteolysis of the Enzyme and a Distinct Inhibitor Profile Megan L. Matthews · ACS Chemical Biology · Scholar only 1 2024 Chemoproteomic Covalent Ligand Discovery as the PROTAC-gonist: The Future of Targeted Degradation Medicines Megan L. Matthews · ACS Central Science · Scholar only 2 2024 Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial Megan L. Matthews · The Lancet Diabetes & Endocrinology · Scholar only 123 2024 Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial Megan L. Matthews · The Lancet Diabetes & Endocrinology · Scholar only 145 2024 Protein phosphatase PP2Cα S-glutathionylation regulates cell migration Megan L. Matthews · Journal of Biological Chemistry · Scholar only 9 2023 Characterizing metabolic drivers of Clostridioides difficile Megan L. Matthews · Journal of Biological Chemistry · Scholar only · needs review 2023 Characterizing metabolic drivers of Clostridioides difficile infection with activity-based hydrazine probes Megan L. Matthews · Frontiers in Pharmacology · Scholar only · needs review 8 2023 Chemoproteomic strategy identified p120-catenin glutathionylation regulates E-cadherin degradation and cell migration Megan L. Matthews · Cell chemical biology · Scholar only 17 2023 eCOVID-19 recommendations map collaborators. Good or best practice statements: Proposal for the operationalisation and implementation of GRADE guidance Megan L. Matthews · BMJ Evid Based Med · Scholar only 24 2023 Phenelzine-based probes reveal Secernin-3 is involved in thermal nociception Megan L. Matthews · Molecular and Cellular Neuroscience · Scholar only 13 2022 Chemoproteomic profiling of protein electrophilic and oxidative post-translational modifications Megan L. Matthews · US Patent App · Scholar only 1 2022 Discovery of Potent and Selective Inhibitors against Protein-Derived Electrophilic Cofactors Megan L. Matthews · Journal of the American Chemical Society · Scholar only 33 2022 Enterococci enhance Clostridioides difficile pathogenesis Megan L. Matthews · Nature · Scholar only 229 2022 Predicting kidney failure, cardiovascular disease and death in advanced CKD patients Megan L. Matthews · Kidney International Reports · Scholar only 21 2022 Progress Toward Understanding Protein Control of Reaction Outcome in the Diverse Reactivity of Iron(II)‐ and 2‐Oxoglutarate‐dependent Oxygenases Megan L. Matthews · The FASEB Journal · Scholar only 2021 Activity-Based Hydrazine Probes for Protein Profiling of Electrophilic Functionality in Therapeutic Targets Megan L. Matthews · ACS Central Science · Scholar only 44 2021 Voices of chemical biology Megan L. Matthews · Nature Chemical Biology · Scholar only 2 2020 Discovery of Electrophiles and Profiling of Enzyme Cofactors Megan L. Matthews · Current Protocols in Chemical Biology · Scholar only 11 2020 Hydrazines as versatile chemical biology probes and drug-discovery tools for cofactor-dependent enzymes Megan L. Matthews · bioRxiv, 2020.06 · Scholar only 2020 Structural and molecular determinants of CCS-mediated copper activation of MEK1/2 Megan L. Matthews · BioRxiv, 2020.05 · Scholar only 4 2019 Evidence for Modulation of Oxygen Rebound Rate in Control of Outcome by Iron(II)- and 2-Oxoglutarate-Dependent Oxygenases Megan L. Matthews · Journal of the American Chemical Society · Scholar only 54 2018 Metal-free class Ie ribonucleotide reductase from pathogens initiates catalysis with a tyrosine-derived dihydroxyphenylalanine radical Megan L. Matthews · Proceedings of the National Academy of Sciences · Scholar only 76 2017 Chemoproteomic profiling and discovery of protein electrophiles in human cells. Megan L. Matthews · Nature Chemistry 108 2017 Design of benzoxathiazin-3-one 1,1-dioxides as a new class of irreversible serine hydrolase inhibitors: discovery of a uniquely selective PNPLA4 inhibitor. Megan L. Matthews · Journal of the American Chemical Society 39 2017 Vanadyl as a stable structural mimic of reactive ferryl intermediates in mononuclear non-heme-iron enzymes. Megan L. Matthews · Inorganic Chemistry 35 2016 Chemical proteomic profiling of human methyltransferases. Megan L. Matthews · Journal of the American Chemical Society 117 2016 Electronic structure of the ferryl intermediate in the a-ketoglutarate dependent non-heme iron halogenase SyrB2: Contributions to H-atom abstraction reactivity. Megan L. Matthews · Journal of the American Chemical Society 119 2015 2-Oxoglutarate-dependent oxygenases Megan L. Matthews · RSC Metallobiology · Scholar only 77 2015 Mechanisms of 2-oxoglutarate-dependent oxygenases: the hydroxylation paradigm and beyond Megan L. Matthews · 2-Oxoglutarate-Dependent Oxygenases 78 2014 Design of activated serine-containing catalytic triads with atomic-level accuracy. Megan L. Matthews · Nature Chemical Biology 111 2014 Direct nitration and azidation of aliphatic carbons by an iron-dependent halogenase. Megan L. Matthews · Nature Chemical Biology 192 2013 Aza-b-lactam compounds and methods of using Megan L. Matthews · WO 2013152272 A1 2013 Elucidation of the Fe(IV)=O intermediate in the catalytic cycle of the halogenase SyrB2. Megan L. Matthews · Nature 301 2013 Elucidation of the iron (IV)–oxo intermediate in the non-haem iron halogenase SyrB2 Megan L. Matthews · Nature · Scholar only 4 2013 Novel approaches for the accumulation of oxygenated intermediates to multi-millimolar concentrations. Megan L. Matthews · Coordination Chemistry Reviews 27 2012 Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric with endocannabinoid substrates. Megan L. Matthews · Chemistry & Biology 257 2011 Protein control of dioxygen activation, substratehydrogen abstraction, and ligand-radical-transfer outcome in the aliphatic halogenase, SyrB2 Megan L. Matthews · The Pennsylvania State University · Scholar only 2 2010 How Aliphatic Halogenases Prevent Competing Hydroxylation: 43 Megan L. Matthews · Protein Science · Scholar only 2010 Remote enzyme microsurgery. Megan L. Matthews · Science 8 2010 The nonribosomal peptide synthetase enzyme DdaD tethers N(b)-fumaramoyl-L-2,3-diaminopropionate for Fe(II)/a-ketoglutarate-dependent epoxidation by DdaC during dapdiamide antibiotic biosynthesis. Megan L. Matthews · Journal of the American Chemical Society 47 2010 The NRPS enzyme DdaD tethers Nβ-fumaramoyl-DAP for Fe (II)/α-ketoglutarate-dependent epoxidation by DdaC during dapdiamide antibiotic biosynthesis Megan L. Matthews · Journal of the American Chemical Society · Scholar only 3 2009 Myo-inositol oxygenase: a radical new pathway for O2 and C-H activation at a nonheme diiron cluster. Megan L. Matthews · Dalton Trans. 72 2009 Substrate positioning controls the partition between halogenation and hydroxylation in the aliphatic halogenase, SyrB2. Megan L. Matthews · Proceedings of the National Academy of Sciences 291 2009 Substrate-triggered formation and remarkable stability of the C–H bond-cleaving chloroferryl intermediate in the aliphatic halogenase, SyrB2. Megan L. Matthews · Biochemistry 300 2007 AurF from Streptomyces thioluteus and a possible new family of manganese/iron oxygenases. Megan L. Matthews · Biochemistry 51
Back to the list

2025 · article · journal

Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial

EClinicalMedicine · Megan L. Matthews

on Scholar
12Scholar citations
noneOpenAlex citations

From the CV

Not in the CV.

Where each field came from

FieldCVOpenAlexScholar
title Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial (used)
year 2025 (used)
venue EClinicalMedicine (used)
kind other (used)
first author Zhou (used)

The value in bold is the one the record uses.

How the records were joined

No decision recorded; a single record.